Josephine Linden was appointed Director of Innoviva, Inc. As of November 6, 2026, Innoviva, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 18, 2026, naming 1 appointment and 1 departure (Form 8-K, May 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Innoviva, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Innoviva, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-18. It names 1 person, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Innoviva, Inc. files it.
Also on the record for Innoviva, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 15.4% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.01% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.79% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 5.63% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 5.8% of the class | 5%+ stakes | Source |
| October 8, 2025 | Stake report, Schedule 13G/A, by BANK OF NOVA SCOTIA | 3.37% of the class | 5%+ stakes | Source |
| September 3, 2025 | Stake report, Schedule 13G/A, by BANK OF NOVA SCOTIA | 5.55% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 7.56% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G, by BANK OF NOVA SCOTIA | 11.36206% of the class | 5%+ stakes | Source |
| August 5, 2025 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 4.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Innoviva, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Innoviva, Inc. and the records around it.
Innoviva, Inc. elsewhere on the record
Companies that share a holder
- BANK OF NOVA SCOTIA also filed stake reports on 19 other companies: CENTRUS ENERGY CORP (Oct 2026), CLEANSPARK, INC. (Oct 2026), Haymaker Acquisition Corp V (Oct 2026)
- Franklin Resources, Inc. also filed stake reports on 41 other companies: Adicet Bio, Inc. (Oct 2026), ALBEMARLE CORPORATION (Oct 2026), Andersen Group Inc. (Oct 2026)
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Bolt Biotherapeutics, Inc. (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026)
Watch Innoviva, Inc.
Get an email when Innoviva, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Innoviva, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Innoviva, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Innoviva, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-18 | In | Director | 8-K, 2026-05-18 | ||
| 2026-05-18 | Out | 8-K, 2026-05-18 |
Who leads Innoviva, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Josephine Linden, appointed (filed 2026-05-18).
New leaders reset buying decisions — get the Full Report on Innoviva, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Innoviva, Inc., with the record behind each one.
Find candidates like Director at Innoviva, Inc.Every change, in the filing's words
Appointed: Josephine Linden, Director
(d) On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the "Linden Effective Date").
Departing: Josephine Linden
In November 2008, Mrs. Linden retired from Goldman, Sachs & Co. as a Partner and Managing Director after having been with the firm for more than 25 years.
- (b) On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc. (the "Board" and the "Company"), in order to focus on the growth of Syndeio BioSciences Inc. ("Syndeio"), where Mr. Small serves as Chief Executive Officer and Mr. DiPaolo is expected to assume an executive position.
- The Company has made a series of investments into Syndeio and anticipates continuing to support Syndeio as a leader in the advancement of therapies for neuropsychiatric and related disorders.
- The resignations of Messrs. Small and DiPaolo did not relate to any disagreement with the Company related to the Company's operations, policies or practices.
- Mrs. Linden is the founder and has been the managing member and principal of Linden Global Strategies LLC, a New York-based investment management firm registered with the Securities and Exchange Commission, since September 2011.
- From September 2010 to July 2011, Mrs. Linden served as an Adjunct Professor in the Finance department of Columbia Business School.
- Mrs. Linden has also served as a public company board member for several companies.
- Mrs. Linden received an M.B.A. from the University of Chicago, with a specialization in Finance, and a B.A. from the University of Sydney.
- It is expected that Mrs. Linden will serve on the Board's Audit Committee.
Tools for this story
Each opens in a new tab, filled in for Innoviva, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.